Crossmark

Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir−bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death

Crossref DOI link: https://doi.org/10.1038/s41388-018-0381-2

Published Online: 2018-07-06

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Johnson, Charlotte E.

Dunlop, Elaine A.

Seifan, Sara

McCann, Henry D.

Hay, Trevor

Parfitt, Geraint J. https://orcid.org/0000-0002-8704-7906
Jones, Ashley T.

Giles, Peter J.

Shen, Ming H.

Sampson, Julian R.

Errington, Rachel J.

Davies, D. Mark

Tee, Andrew R.
Funding

Funding for this research was provided by:

Cancer Research Wales (Ymchwil Canser Cymru) (508502, 508502, 508502)

Tuberous Sclerosis Association (TSA) (2013-P05, 2013-F03, 2015-S01, 2013-P05, 2015-S01)

Tuberous Sclerosis Alliance (TS Alliance) (03-15)

Health and Care Research Wales (grant reference number: CA05)
License Information

Text and Data Mining valid from 2018-07-06
More Information

Article History

Received: 10 January 2018

Revised: 10 May 2018

Accepted: 31 May 2018

First Online: 6 July 2018

Compliance with ethical standards

:

: RJE is non-executive director of Biostatus Ltd, the vendor of DRAQ7. The remaining authors declare that they have no conflict of interests.